|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||41.65 - 42.15|
|52 Week Range||35.05 - 44.54|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
Despite the recent pullback, many investors still maintain a bullish market outlook. Nevertheless, ETF investors and financial advisors should monitor the pulse of the market in case of any sudden shifts. ...
The company will be launching its Phase 3 TAHOE study to compare Rova-T with topotecan, the only therapy in second line SCLC approved by the FDA (U.S. Food & Drug Administration). AbbVie also aims to establish the importance of targeting tumor-initiating cells in treating solid tumors. Beyond 2020, the company plans to launch the MERU study, which will enable Rova-T to expand its label in the first line SCLC maintenance indication.
NEW YORK, Jan. 03, 2018-- WisdomTree, an exchange-traded fund and exchange-traded product sponsor and asset manager, today announced the addition of the WisdomTree Emerging Markets ex-State-Owned Enterprises ...
While a rise in interest rates would diminish the attractiveness of dividend stocks, investors are chasing these on optimism surrounding the biggest tax overhaul in decades.
Stocks were narrowly mixed Wednesday, with the Dow Jones industrial average holding a gain despite an Apple drop.
Contract oil and gas well driller Helmerich & Payne (HP) recorded a sharp drop in its 2016 operating revenue due to declines in its US drilling, offshore, and international segments.…
W.W. Grainger's (GWW) PE ratio of 16.3x compares to a sector average of 29.3x. The dividend yield of 3.2% compares to a sector average of 1.6%.